GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (NAS:ZEAL) » Definitions » Debt-to-Asset

Zealand Pharma A/S (Zealand Pharma A/S) Debt-to-Asset : 0.06 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Zealand Pharma A/S Debt-to-Asset?

Zealand Pharma A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.44 Mil. Zealand Pharma A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $15.01 Mil. Zealand Pharma A/S's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $289.69 Mil. Zealand Pharma A/S's debt to asset for the quarter that ended in Dec. 2023 was 0.06.


Zealand Pharma A/S Debt-to-Asset Historical Data

The historical data trend for Zealand Pharma A/S's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Debt-to-Asset Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.07 0.38 0.29 0.06

Zealand Pharma A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.38 0.06 0.05 0.06

Competitive Comparison of Zealand Pharma A/S's Debt-to-Asset

For the Biotechnology subindustry, Zealand Pharma A/S's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Debt-to-Asset falls into.



Zealand Pharma A/S Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Zealand Pharma A/S's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(2.437 + 15.008) / 289.693
=0.06

Zealand Pharma A/S's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(2.437 + 15.008) / 289.693
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma A/S  (NAS:ZEAL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Zealand Pharma A/S Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.